Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Belani

Showing results (51-60 of 298) with videos related to

Pageof 30
Sort By:
Current Molecular Pharmacology|July 17, 2015
Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure)Xin Liu, Chandra P Belani
Future Oncology (London, England)|March 27, 2007
Role of bevacizumab for the treatment of non-small-cell lung cancerSuresh Ramalingam, Chandra P Belani
Expert Opinion on Therapeutic Targets|January 18, 2007
Recent advances in targeted therapy for non-small cell lung cancerSuresh Ramalingam, Chandra P Belani
Clinical Lung Cancer|February 8, 2005
Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinibChandra P Belani, Sakkaraiappan Ramalingam
Clinical Lung Cancer|December 5, 2003
Impact of INTACT: do we change the target or the aim?Sakkaraiappan Ramalingam, Chandra P Belani
Clinical Lung Cancer|January 15, 2004
Role of topoisomerase I inhibitors in small-cell lung cancerS Shihabi, C P Belani
Seminars in Oncology|February 26, 2004
State-of-the-art chemotherapy for advanced non-small cell lung cancerSakkaraiappan Ramalingam, Chandra P Belani
Clinical Lung Cancer|August 16, 2005
Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?Chandra P Belani, Suresh Ramalingam
Seminars in Oncology|May 29, 1999
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostineG Selvaggi, C P Belani
Expert Opinion on Pharmacotherapy|July 22, 2004
Paclitaxel for non-small cell lung cancerSakkaraiappan Ramalingam, Chandra P Belani
Pageof 30

Showing results (51-60 of 298) with videos related to

Sort By:
Pageof 30
Current Molecular Pharmacology|July 17, 2015
Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure)Xin Liu, Chandra P Belani
Future Oncology (London, England)|March 27, 2007
Role of bevacizumab for the treatment of non-small-cell lung cancerSuresh Ramalingam, Chandra P Belani
Expert Opinion on Therapeutic Targets|January 18, 2007
Recent advances in targeted therapy for non-small cell lung cancerSuresh Ramalingam, Chandra P Belani
Clinical Lung Cancer|February 8, 2005
Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinibChandra P Belani, Sakkaraiappan Ramalingam
Clinical Lung Cancer|December 5, 2003
Impact of INTACT: do we change the target or the aim?Sakkaraiappan Ramalingam, Chandra P Belani
Clinical Lung Cancer|January 15, 2004
Role of topoisomerase I inhibitors in small-cell lung cancerS Shihabi, C P Belani
Seminars in Oncology|February 26, 2004
State-of-the-art chemotherapy for advanced non-small cell lung cancerSakkaraiappan Ramalingam, Chandra P Belani
Clinical Lung Cancer|August 16, 2005
Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?Chandra P Belani, Suresh Ramalingam
Seminars in Oncology|May 29, 1999
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostineG Selvaggi, C P Belani
Expert Opinion on Pharmacotherapy|July 22, 2004
Paclitaxel for non-small cell lung cancerSakkaraiappan Ramalingam, Chandra P Belani
Pageof 30